Contact Us
Drug Search Results
More Filters [+]

Galiximab

Alternative Names: galiximab, idec-114, idec114, idec 114
Latest Update: 2022-05-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CD80 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Galiximab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Lymphoma, Non-Hodgkin|Follicular Lymphoma

Phase 2: Hodgkin Lymphoma|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CALGB-50602

P2

Completed

Hodgkin Lymphoma

2011-09-01

2005-003836-22

P3

Completed

Lymphoma, Non-Hodgkin|Follicular Lymphoma

2011-04-13

114-NH-103

P1

Terminated

Follicular Lymphoma|Lymphoma, Non-Hodgkin

2010-11-01

114-NH-302

P3

Terminated

Follicular Lymphoma|Lymphoma, Non-Hodgkin

2010-01-01

Recent News Events

Date

Type

Title

05/18/2022

PubMed

 Immunotherapy in indolent Non-Hodgkin's Lymphoma.

01/06/2021

PubMed

 CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions